Aeterna prostate cancer drug shows promise

Data showed that the first primary efficacy endpoint of the study of finding a tolerable dosage regimen ensuring continuous suppression of testosterone at castration level was achieved at a dose of 130 mg administered intramuscularly every four weeks. The second primary efficacy endpoint relating to time for onset of action was also well achieved as the results showed that all patients had testosterone in castration range within two days after dosing.

Furthermore, a secondary efficacy endpoint, related to a decrease in prostate specific antigen (PSA) level of at least 50%, was achieved with all patients.

“These phase II data provide further evidence that ozarelix, most importantly, is well tolerated and effective while demonstrating a unique very fast onset of action,” said Dr Jurgen Engel, executive vice president, Global R&D at Aeterna Zentaris.

“We believe ozarelix has the potential to be beneficial in the treatment of additional hormone-dependent cancers and look forward to continuing its further clinical development.”